Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2661850 | 0.82 | NAPRT (0.48) | KDM4ENAPRTSMN1; SMN2CYP2C9NAMPT | |
| SCHEMBL6719988 | 0.77 | SRC (0.50) | KDM4ESMN1; SMN2LMNA | |
| SCHEMBL27455320 | 0.77 | NAPRT (0.43) | KDM4ENAPRTSMN1; SMN2CYP2C9NAMPT | |
| SCHEMBL5147826 | 0.77 | SMN1; SMN2 (0.53) | NAPRTSMN1; SMN2CFTRSLC6A2SLC6A4 | |
| SCHEMBL27445792 | 0.77 | NAPRT (0.50) | NAPRTSMN1; SMN2CYP2C9NAMPTCFTR | |
| SCHEMBL20784538 | 0.75 | CFTR (0.54) | KDM4ESMN1; SMN2CFTRSLC6A2SLC6A4 | |
| SCHEMBL18022518 | 0.75 | CFTR (0.54) | KDM4ESMN1; SMN2CFTRSLC6A2SLC6A4 | |
| SCHEMBL8277374 | 0.75 | CFTR (0.54) | KDM4ESMN1; SMN2CFTRSLC6A2SLC6A4 | |
| SCHEMBL19413051 | 0.75 | CFTR (0.54) | KDM4ESMN1; SMN2CFTRSLC6A2SLC6A4 | |
| SCHEMBL28179698 | 0.75 | NAPRT (0.48) | KDM4ENAPRTSMN1; SMN2CFTRSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926274-B2 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| EP-2650282-B1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO (JP) | 2017-06-07 | — | — | EP | disclosed |
| EP-2650283-B1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-20150141653-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2015-05-21 | — | — | US | disclosed |
| US-9000156-B2 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20140323724-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2014-10-30 | — | — | US | disclosed |
| EP-2141149-B1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2014-10-29 | — | — | EP | disclosed |
| EP-2650283-A1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2650282-A1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20120071656-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20100121054-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071656-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | KDM4E 797/4885NAPRT 2050/4885SMN1; SMN2 2375/4885 |
| US-20140323724-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | KDM4E 797/4885NAPRT 2050/4885SMN1; SMN2 2375/4885 |
| US-20150141653-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | KDM4E 797/4885NAPRT 2050/4885SMN1; SMN2 2375/4885 |
| US-20100121054-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | KDM4E 642/4885NAPRT 2215/4885SMN1; SMN2 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.